BidaskClub upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a buy rating in a report published on Thursday.

Several other equities analysts also recently weighed in on CORT. Stifel Nicolaus began coverage on shares of Corcept Therapeutics in a report on Thursday, August 31st. They issued a buy rating and a $20.00 price target on the stock. Piper Jaffray Companies set a $18.00 price target on shares of Corcept Therapeutics and gave the stock a buy rating in a report on Thursday, August 24th. Finally, Zacks Investment Research downgraded shares of Corcept Therapeutics from a buy rating to a hold rating in a report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $18.20.

Corcept Therapeutics (NASDAQ CORT) opened at $16.61 on Thursday. Corcept Therapeutics has a fifty-two week low of $6.70 and a fifty-two week high of $20.77. The firm has a market cap of $1,895.60, a P/E ratio of 57.28 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The business had revenue of $42.70 million during the quarter, compared to analyst estimates of $41.64 million. During the same quarter last year, the company posted $0.02 EPS. Corcept Therapeutics’s quarterly revenue was up 96.8% compared to the same quarter last year. research analysts expect that Corcept Therapeutics will post 0.47 earnings per share for the current year.

In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $16.72, for a total value of $133,760.00. Following the sale, the insider now owns 8,000 shares in the company, valued at approximately $133,760. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The disclosure for this sale can be found here. Corporate insiders own 19.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its position in Corcept Therapeutics by 111.2% in the 2nd quarter. Bank of Montreal Can now owns 34,931 shares of the biotechnology company’s stock worth $413,000 after purchasing an additional 18,389 shares in the last quarter. Birchview Capital LP boosted its position in Corcept Therapeutics by 58.3% in the 2nd quarter. Birchview Capital LP now owns 95,000 shares of the biotechnology company’s stock worth $1,121,000 after purchasing an additional 35,000 shares in the last quarter. California Public Employees Retirement System boosted its position in Corcept Therapeutics by 3.6% in the 2nd quarter. California Public Employees Retirement System now owns 148,200 shares of the biotechnology company’s stock worth $1,749,000 after purchasing an additional 5,200 shares in the last quarter. Rhumbline Advisers boosted its position in Corcept Therapeutics by 21.5% in the 2nd quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 15,494 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in Corcept Therapeutics by 3,409.5% in the 2nd quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock worth $7,472,000 after purchasing an additional 615,180 shares in the last quarter. Institutional investors and hedge funds own 64.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/corcept-therapeutics-cort-upgraded-by-bidaskclub-to-buy/1770416.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.